Beta-2 Adrenergic Receptor Protein
Introduction
Beta 2 Adrenergic Receptor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
<div class="infobox infobox-protein"> [@supsup2026a]
<table> [@supsup1993]
<tr><th colspan="2" style="background:#4477AA; color:white; text-align:center">ADRB2</th></tr> [@supsup2013]
<tr><th>Protein Name</th><td>Beta-2 Adrenergic Receptor</td></tr> [@supsup2007]
<tr><th>Gene</th><td>[ADRB2](/genes/adrb2)</td></tr> [@supsup2018]
<tr><th>UniProt ID</th><td>[P07550](https://www.uniprot.org/uniprot/P07550)</td></tr> [@supsup2012]
<tr><th>PDB IDs</th><td>2RHY, 3KJ6, 4G5R</td></tr> [@supsup2005]
<tr><th>Molecular Weight</th><td>46.5 kDa</td></tr>
<tr><th>Subcellular Localization</th><td>Plasma Membrane</td></tr>
<tr><th>Protein Family</th><td>G Protein-Coupled Receptor (GPCR) - Adrenergic Receptor Family</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">Anxiety</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">91 edges</a></td>
</tr>
</table>
</div>
Function
...
Beta-2 Adrenergic Receptor Protein
Introduction
Beta 2 Adrenergic Receptor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
<div class="infobox infobox-protein"> [@supsup2026a]
<table> [@supsup1993]
<tr><th colspan="2" style="background:#4477AA; color:white; text-align:center">ADRB2</th></tr> [@supsup2013]
<tr><th>Protein Name</th><td>Beta-2 Adrenergic Receptor</td></tr> [@supsup2007]
<tr><th>Gene</th><td>[ADRB2](/genes/adrb2)</td></tr> [@supsup2018]
<tr><th>UniProt ID</th><td>[P07550](https://www.uniprot.org/uniprot/P07550)</td></tr> [@supsup2012]
<tr><th>PDB IDs</th><td>2RHY, 3KJ6, 4G5R</td></tr> [@supsup2005]
<tr><th>Molecular Weight</th><td>46.5 kDa</td></tr>
<tr><th>Subcellular Localization</th><td>Plasma Membrane</td></tr>
<tr><th>Protein Family</th><td>G Protein-Coupled Receptor (GPCR) - Adrenergic Receptor Family</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">Anxiety</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">91 edges</a></td>
</tr>
</table>
</div>
Function
The beta-2 adrenergic receptor (β2-AR) is a G protein-coupled receptor that responds to epinephrine and norepinephrine. It is widely expressed in the central nervous system and peripheral tissues, where it regulates diverse physiological processes including bronchodilation, vasodilation, glycogenolysis, and lipolysis. In the brain, β2-AR is expressed in regions involved in memory consolidation and emotional processing, including the hippocampus, amygdala, and prefrontal cortex.
Structure
The β2-AR is a prototypical class A GPCR consisting of seven transmembrane helices (TM1-TM7) connected by three extracellular loops (ECL1-ECL3) and three intracellular loops (ICL1-ICL3). The receptor contains:
- N-terminal extracellular domain: Short, glycosylated
- Transmembrane domain: Seven α-helices forming the ligand-binding pocket
- Intracellular domain: Couples to G proteins and contains phosphorylation sites
- C-terminal tail: Palmitoylated for membrane anchoring
Molecular Mechanisms
G Protein Signaling
Agonist binding → conformational change in receptor
Gαs coupling → activation of adenylyl cyclase
cAMP production → activation of protein kinase A (PKA)
Phosphorylation of target proteins → cellular responsesβ-Arrestin Pathway
- β-arrestin recruitment after phosphorylation
- Receptor internalization
- β-arrestin-dependent signaling (MAPK activation)
Key Interactions
- Gαs/ Golf: Primary G protein coupling
- β-arrestin 1/2: For desensitization and signaling
- GRK2/3/5/6: For receptor phosphorylation
Expression Pattern
Central Nervous System
- [Hippocampus](/brain-regions/hippocampus): CA1-CA3 pyramidal [neurons](/entities/neurons), dentate gyrus
- [Cortex](/brain-regions/cortex): Layer V pyramidal neurons
- Amygdala: Basolateral and central nuclei
- Cerebellum: Purkinje cells
- Thalamus: Various nuclei
- Locus coeruleus: Noradrenergic neurons
Peripheral Tissues
- Lung bronchial smooth muscle
- Cardiac myocardium
- Skeletal muscle
- Adipose tissue
- Liver
Role in Neurodegeneration
Alzheimer's Disease
- Memory consolidation: β2-AR in hippocampal [LTP](/mechanisms/long-term-potentiation) and memory
- [Aβ](/proteins/amyloid-beta) effects: [Aβ](/proteins/amyloid-beta) may dysregulate β2-AR signaling
- Neuroinflammation: β2-AR modulates microglial activation
- Therapeutic potential: β2-agonists being investigated
Parkinson's Disease
- Neuroprotection: β2-AR activation may protect dopaminergic neurons
- L-dopa response: Altered β2-AR signaling in PD
- Olfactory dysfunction: β2-AR in olfactory bulb
Other Disorders
- Depression: β2-AR in mood regulation
- Anxiety: Stress-induced β2-AR changes
- ADHD: Noradrenergic modulation
Therapeutic Targeting
Agonists
| Drug | Application | Status |
|------|-------------|--------|
| Albuterol | Asthma, bronchodilation | Approved |
| Formoterol | Long-acting bronchodilator | Approved |
| Salmeterol | Asthma/COPD | Approved |
| Terbutaline | Bronchodilation | Approved |
Antagonists (Beta-Blockers)
| Drug | Application | Status |
|------|-------------|--------|
| Propranolol | Hypertension, anxiety | Approved |
| Metoprolol | Hypertension, HF | Approved |
| Atenolol | Hypertension | Approved |
| Carvedilol | HF, hypertension | Approved |
CNS-Targeting Agents
- Clenbuterol: Brain-penetrant β2-agonist (research)
- ICI-118551: Selective β2-antagonist (research)
Clinical Considerations
Side Effects
- Tremor (muscle β2-AR activation)
- Tachycardia (cardiac β1-AR activation)
- Hypokalemia (β2-AR in liver)
- Hyperglycemia (β2-AR in liver)
Drug Interactions
- β-blockers may blunt epinephrine response
- Cocaine + β-agonists = cardiovascular risk
Animal Models
- ADRB2 knockout mice: Altered stress response, memory deficits
- Overexpression studies: Enhanced memory consolidation
- β2-AR antagonists: Impaired remote memory
Background
The study of Beta 2 Adrenergic Receptor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- [ADRB2 Gene](/genes/adrb2)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [GPCR Signaling](/mechanisms/gpcr-signaling)
- [Adrenergic Receptors](/mechanisms/dopaminergic-neuron-vulnerability)
- [Norepinephrine Signaling](/mechanisms/dopaminergic-neuron-vulnerability)
- [Beta Blockers](/mechanisms/dopaminergic-neuron-vulnerability)
External Links
- [UniProt: P07550](https://www.uniprot.org/uniprot/P07550)
- [PDB Database](https://www.rcsb.org/)
- [NCBI Gene: ADRB2](https://www.ncbi.nlm.nih.gov/gene/154)
- [IUPHAR: β2-AR](https://www.guidetopharmacology.org/GTOR7-2.xml)
- [GeneCards: ADRB2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ADRB2)
References
Unknown, <sup>1</sup> ADRB2 protein. UniProtKB. Retrieved 2026-03-04 (2026)
Unknown, <sup>2</sup> PDB: 2RHY, 3KJ6. Retrieved 2026-03-04 (2026)
<sup>3</sup> Strosberg AD, (1993) (1993)
<sup>4</sup> Lefkowitz RJ, (2013) (2013)
<sup>5</sup> Ramos BP, Arnsten AF, (2007) (2007)
<sup>6</sup> Yu G, et al, (2018) (2018)
<sup>7</sup> O'Donnell J, et al, (2012) (2012)
<sup>8</sup> Summers RJ, et al, (2005) (2005)